Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma

被引：0
|
作者：
S Lee
Y H Park
K H Kim
E Y Cho
Y C Ahn
K Kim
Y-M Shim
J S Ahn
K Park
Y-H Im
机构：
[1] Samsung Medical Center,Division of Hematology
[2] Sungkyunkwan University School of Medicine,Oncology, Department of Medicine
[3] Samsung Medical Center,Department of Pathology
[4] Sungkyunkwan University School of Medicine,Department of Radiation Oncology
[5] Samsung Medical Center,Department of Thoracic Surgery
[6] Sungkyunkwan University School of Medicine,undefined
[7] Samsung Medical Center,undefined
[8] Sungkyunkwan University School of Medicine,undefined
来源：
British Journal of Cancer | 2010年 / 103卷
关键词：
oesophageal cancer; capecitabine; cisplatin; thymidine synthase (TS); thymidine phosphorylase (TP); excesion repair cross-complementation group 1 (ERCC1);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：845 / 851
页数：6
相关论文
共 50 条
  • [41] Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy
    Yun, Jina
    Kim, Kyoung-Mee
    Kim, Seung Tae
    Kim, Jung-Hoon
    Kim, Jung A.
    Kong, Jee Hyun
    Lee, Soo Hyeon
    Won, Young-Woong
    Sun, Jong-Mu
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2010, 42 (02): : 101 - 106
  • [42] HIGH EXPRESSION OF EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1 PROTEIN PREDICTS POOR OUTCOME IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH PLATINUM-BASED THIRD-GENERATION CHEMOTHERAPY DOUBLETS
    Jeong, S. H.
    Choi, Y. W.
    Lee, H. W.
    Kang, S. Y.
    Jung, J. H.
    Han, J. H.
    Choi, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 114 - 114
  • [43] Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma
    Luo, Huiyan
    Lu, Jin
    Bai, Yuxian
    Mao, Teng
    Wang, Jun
    Fan, Qingxia
    Zhang, Yiping
    Zhao, Kuaile
    Chen, Zhendong
    Gao, Shegan
    Li, Jiancheng
    Fu, Zhichao
    Gu, Kangsheng
    Liu, Zhihua
    Wu, Lin
    Zhang, Xiaodong
    Feng, Jifeng
    Sheng, Zhen
    Zeng, Wanqin
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
    Li, J.
    Chen, Z.
    Bai, Y.
    Liu, B.
    Li, Q.
    Zhou, J.
    Zhang, J.
    Deng, T.
    Zhou, F.
    Gao, S.
    Yang, S.
    Ye, F.
    Chen, L.
    Bai, W.
    Yin, X.
    Xu, Y.
    Hu, J.
    Ni, J.
    Wang, B.
    Yang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S181 - S182
  • [45] The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy
    Huang, Jiwei
    Su, Ruopeng
    Chen, Zeyu
    Jiang, Shuai
    Chen, Minfeng
    Yuan, Yichu
    Hu, Hailong
    Fu, Changde
    Huang, Zhiyang
    Wang, Zhenyu
    Zheng, Bing
    Li, Chancan
    Wang, Zaoyu
    Bao, Yige
    Cai, Ming
    Guo, Jianming
    Wei, Qiang
    Xue, Wei
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [46] Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.
    Wang, Wei
    Lin, Shuimiao
    Wang, Rong
    Wu, Dehua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS482 - TPS482
  • [47] First-line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study
    Cheng, Lei
    Chai, Congna
    Liu, Yingqi
    Jiao, Jianjun
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [48] SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
    Mu, Lan
    Song, Yan
    Zhao, Kuaile
    Liu, Ying
    Fan, Qingxia
    Wang, Xi
    Li, Qun
    Wang, Xiaopeng
    Huang, Jing
    THORACIC CANCER, 2021, 12 (09) : 1373 - 1381
  • [49] Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
    Greil, R.
    Chau, I
    Doki, Y.
    Ajani, J. A.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    el Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, Ignez M.
    Holtved, E.
    Xynos, I
    Liu, X.
    Lei, M.
    Kondo, K.
    Kato, K.
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 81 - 82
  • [50] Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy
    Vassalou, Helen
    Stathopoulos, Efstathios
    Fiolitaki, Georgia
    Koutsopoulos, Anastasios
    Voutsina, Alexandra
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    LUNG CANCER, 2013, 82 (02) : 324 - 329
12345